Aprotinin

Annals of Pharmacotherapy

Volumn 30, Issue 4, 1996, Pages 372-380

  Robert, Sylvie ^a   Wagner, Bertil K J ^b,c   Boulanger, Michelle ^d   Richer, Monique ^e  

^a PFIZER INC   (United States)

^b RUTGERS UNIVERSITY   (United States)

^c UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^d LAVAL UNIVERSITY   (Canada)

^e UNIVERSITÉ LAVAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFIBRINOLYTIC AGENT; APROTININ; SERINE PROTEINASE INHIBITOR;

ACUTE KIDNEY FAILURE; BLEEDING; CARDIOTOXICITY; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; DRUG EFFICACY; DRUG MECHANISM; ENZYME INHIBITION; GRAFT OCCLUSION; HEMOSTASIS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; REVIEW; THROMBOSIS; TREATMENT INDICATION;

APROTININ; CORONARY ARTERY BYPASS; DRUG INTERACTIONS; HEMOSTASIS, SURGICAL; HEMOSTATICS; HUMANS;

EID: 0029870984     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1177/106002809603000410     Document Type: Article

References (68)

1. Woodman RC, Harker LA. Bleeding complications associated with cardiopulmonary bypass. Blood 1990;76:1680-97.
2. Bracey AW, Radovancevic R. The hematologic effects of cardiopulraonary bypass and the use of hemotherapy in coronary artery bypass grafting. Arch Pathol LabMed 1994;118:411-6.
3. Jansen NJ, van Oeveren W, van Vliet M, Stoutenbeek CP, Eysman L, Wildevuur CR. The role of different types of corticosteroids on the inflammatory mediators in cardiopulmonary bypass. Eur J Cardiothorac Surg 1991;5:211-7.
4. Munkvad S. Fibrinolysis in patients with acute ischaemic heart disease. Dan Med Bull 1993;40:383-407.
5. Package insert. Trasylol (aprotinin). West Haven, CT: Miles, January 1994.
6. Package insert. Trasylol (aprotinin). Etobicoke, Ontario, Canada: Miles Canada, February 1993.
7. Verstraete M. Clinical application of inhibitors of fibrinolysis. Drugs 1985;29:236-61.
8. Westaby S. Aprotinin in perspective. Ann Thorac Surg 1993;55:1033-41.
9. Royston D. High-dose aprotinin therapy: a review of the first five years' experience. J Cardiothorac Vase Anesth 1992;6:76-100.
10. Becker RC, Alpert JS. The impact of medical therapy on hemorrhagic complications following coronary artery bypass grafting. Arch Intern Med 1990;150:2016-21.
11. van Oeveren W, Jansen NJG, Bidstrup BP, Royston D, Westaby S, Neuhof H, et al. Effects of aprotinin on hemostatic mechanisms during cardiopulmonary bypass. Ann Thorac Surg 1987;44:640-5.
12. Taylor KM. Perioperative approaches to coagulation defects. Ann Thorac Surg 1993;56:S78-82.
13. Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, et al. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion. J Thorac Cardiovasc Surg 1993;106:1-10
14. Levy JH, Bailey JM, Salmenpera M. Pharmacokinetics of aprotinin in preoperative cardiac surgical patients. Anesthesiology 1994;80:1013-8.
15. van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CRH. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass. J Thorac Cardiovasc Surg 1990;99:788-97.
16. Huang H, Ding W, Su Z, Zhang W. Mechanism of the preserving effect of aprotinin on platelet function and its use in cardiac surgery. J Thorac Cardiovasc Surg 1993;106:11-8.
17. Lavee J, Savion N, Smolinsky A, Goor DA, Mohr R. Platelet protection by aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1992;53:477-81
18. de Smet AAEA, Joen MCN, van Oeveren W, Roozendaal KJ, Harder MP, Eijsman L, et al. Increased anticoagulation during cardiopulmonary bypass, by aprotinin. J Thorac Cardiovasc Surg 1990;100:520-7.
19. Blauhut B, Gross C, Necek S, Doran JE, Spath P, Lundsgaard-Hansen P. Effects of high-dose aprotinin on blood loss, platelet function, fibrinolysis, complement, and renal function after cardiopulmonary bypass. J Thorac Cardiovasc Surg 1991;101:958-67.
20. Dietrich W, Barankay A, Hahnel CH, Richter JA. High-dose aprotinin therapy in cardiac surgery: three years' experience in 1,784 patients. J Cardiothorac Vase Anesth 1992;6:324-7.
21. Mueller-Esterl W, Oettl A, Trucheit E, Fritz H. Monitoring of aprotinin plasma levels by an enzyme-linked immunosorbent assay (ELISA). Fresenius Z Anal Chem 1984;317:718-21.
22. Dietrich W, Spannagl M, Jochum M, Wendt P, Schramm W, Barankay A, et al. Influence of high-dose aprotinin treatment on blood loss and coagulation patterns in patients undergoing myocardial revascularization. Anesthesiology 1990;73:1119-26.
23. Harder MP, Eijsman L, Roozendaal KJ, van Oeveren W, Wildevuur CRH. Aprotinin reduces intraoperative and postoperative blood loss in membrane oxygenator cardiopulmonary bypass Ann Thorac Surg 1991;51:936-41.
24. Havel M, Teufelsbauer H, Knobl P, Dalmatiner R, Jaksch P, Zwölfer W, et al. Effect of intraoperative aprotinin administration on postoperative bleeding in patients undergoing cardiopulmonary bypass operation. J Thorac Cardiovasc Surg 1991;101:968-72.
25. Vedrinne C, Girard C, Jegaden O, Blanc P, Bouvier H, Ffrench P, et al. Reduction in blood loss and blood use after cardiopulmonary bypass with high-dose aprotinin versus autologous fresh whole blood transfusion. J Cardiothorac Vase Anesth 1992;6:319-23.
26. Alajmo F, Catamai G, Perna AM, Melissano G, Pretelli P, Palmarini MF, et al. High-dose aprotinin: hemostatic effects in open heart operations. Ann Thorac Surg 1989;48:536-9.
27. Bidstrup BP, Royston D, Sapsford RN, Taylor KM, Cosgrove DM. Reduction in blood loss and blood use after cardioputmonary bypass with high-dose aprotinin (Trasylol). J Thorac Cardiovasc Surg 1989;97:364-72.
28. Royston D. Taylor KM, Bidstrup BP, Sapsford RN. Effect of aprotinin on need for blood transfusion after repeat open-heart surgery. Lancet 1987;2:1289-91.
29. Lemmer JH, Stanford W, Bonney SL, Breen JF, Chomka EV, Eldredge WJ. et al. Aprotinin for coronary bypass operations: efficacy, safety, and influence on early saphenous vein graft patency. J Thorac Cardiovasc Surg 1994;107:543-53.
30. Harker LA. Clinical trials evaluating platelet-modifying drugs in patients with atherosclerotic cardiovascular disease and thrombosis. Circulation 1986;73:206-23.
31. Murkin JM, Lux J, Shannon NA, Guiraudon GM, Menkis AH, McKenzie FN, et al. Aprotinin significantly decreases bleeding and transfusion requirements in patients receiving aspirin and undergoing cardiac operations. J Thorac Cardiovasc Surg 1994,107:554-61.
32. Tabuchi N, Huet RCG, Sturk A, Eijsman L, Wildevuur CRH. Aprotinin preserves hemostasis in aspirin-treated patients undergoing cardiopulmonary bypass. Ann Thorac Surg 1994;58:1036-9.
33. Carrel T, Bauer E, Laske A, von Segesser L, Turina M. Low-dose aprotinin for reduction of blood loss after cardiopulmonary bypass (letter). Lancet 1991,337.673.
34. Lavee J, Raviv Z, Smolinsky A, Savion N, Varon D, Goor DA, et al. Platelet protection by low-dose aprotinin in cardiopulmonary bypass: electron microscopic study. Ann Thorac Surg 1993;55:114-9
35. Bailey CR, Wielogorski AK. Randomised placebo controlled double-blind study of two low-dose aprotinin regimens in cardiac surgery. Br Heart J 1994;71:349-53.
36. Kawasuji M, Ueyama K, Sakakibara N, Tedoriya T, Matsunaga Y, Misaki T, et al. Effect of low-dose aprotinin on coagulation and fibrinolysis in cardiopulmonary bypass. Ann Thorac Surg 1993;55:1205-9.
37. Bailey CR, Kelleher AA, Wielogorski AK. Randomized placebo-controlled double-blind study of three aprotinin regimens in primary cardiac surgery. Br J Surg 1994;81:969-73.
38. Cosgrove DM, Heric B, Lytle BW, Taylor PC, Novoa R, Golding LAR, et al Aprotinin therapy for reoperative myocardial revascularization: a placebo-controlled study. Ann Thorac Surg 1992;54:1031-8.
39. Bidstrup BP, Underwood SR, Sapsford RN, Streets EM, Lincoln JCR. Effect of aprotinin (Trasylol) on aorta-coronary bypass graft patency. J Thorac Cardiovasc Surg 1993;105:147-53.
40. Havel M, Grabenwöger F, Schneider J, Laufer G, Wollenek G, Owen A, et al Aprotinin does not decrease early graft patency after coronary artery bypass grafting despite reducing postoperative bleeding and use of donated blood. J Thorac Cardiovasc Surg 1994;107:807-10.
41. Laub GW, Riebman JB, Chen C, Adkins MS, Anderson WA, Fernandez J, et al. The impact of aprotinin on coronary artery graft patency. Chest 1994;106:1370-5.
42. Bidstrup BP, Hamson J, Royston D, Taylor KM, Treasure T. Aprotinin therapy in cardiac operations a report on use in 41 cardiac centers in the United Kingdom. Ann Thorac Surg 1993;55:971-6.
43. Dietrich W, Mössinger H, Spannagl M, Jochum M, Wendt P, Barankay A. et al. Hemostatic activation during cardiopulmonary bypass with different aprotinin dosages in pediatric patients having cardiac operations. J Thorac Cardiovasc Surg 1993;105:712-20.
44. Herynkopf F, Luccese F, Pereira E, Kalil R, Prates P, Nesralla IA. Aprotinin in children undergoing correction of congenital heart defects. J Thorac Cardiovasc Surg 1994;108:517-21.
45. Efstratiadis T, Munsch C, Crossman D, Taylor K. Aprotinin used in emergency coronary operation after streptokinase treatment. Ann Thorac Surg 1991;52:1320-1.
46. Akhtar TM, Goodchild CS, Boylan MKG. Reversal of streptokinase-induced bleeding with aprotinin for emergency cardiac surgery. Anaesthesia 1992;47:226-8.
47. Valentine S, Williamson P, Sutton D. Reduction of acute haemorrhage with aprotinin. Anaesthesia 1993;48.405-6.
48. Feeley TW, Rinsky LA. Use of aprotinin to reduce intraoperative bleeding. West J Med 1993;159:189-92.
49. Janssens M, Joris J, David JL, Lemaire R, Lamy M. High-dose aprotinin reduces blood loss in patients undergoing total hip replacement surgery. Anesmesiology 1994;80:23-9.
50. Royston D. Aprotinin therapy in heart and heart-lung transplantation. J Heart Lung Transplant 1993;12:S19-25.
51. Suárez M, Sangro B, Herrero JI, Pieardi A, Páramo JA, Quiroga J, et al. Effectiveness of aprotinin in orthotopic liver transplantation. Semin Thromb Hemost 1993;19:292-6.
52. Patrassi GM, Viero M, Sartori MT, De Silvesrro G, Rossaro L, Burra P, et al. Aprotinin efficacy on intraoperative bleeding and transfusion requirements in orthotopic liver transplantation. Transfusion 1994;34:507-11.
53. Weite M, Groh J, Azad S, Anthuber M, Haller M, Kratzer MAA. Effect of aprotinin on coagulation parameters in liver transplantation. Semin Thromb Hemost 1993;19:297-9.
54. Groh J, Weite M, Azad SC, Anthuber M, Haller M, Kratzer MAA. Does aprotinin really reduce blood loss in orthotopic liver transplantation? Semin Thromb Hemost 1993;19:306-8.
55. Grosse H, Lobbes W, Frambach M, Ringe B, Barthels M. Influence of high-dose aprotinin on hemostasis and blood requirement in orthotopic liver transplantation Semin Thromb Hemost 1993;19:302-5
56. Bechstein WO, Riess H, Blumhardt G, Himmelreich G, Jochum M, Gerlach H, et al. Aprotinin in orthotopic liver transplantation. Semin Thromb Hemost 1993;19:262-7.
57. Groh J, Welte M, Azad SC, Forst H, Pratschke E, Kratzer MAA. Does aprotinin affect blood loss in liver transplantation (letter)? Lancet 1992;340:173.
58. Dewachter P, Mouton C, Massen C, Guéant JL, Haberer JP. Anaphylactic reaction to aprotinin during cardiac surgery. Anaesthesia 1993;48:1110-1.
59. Proud G, Chamberlain J. Anaphylactic reaction to aprotinin. Lancet 1976;2:48-9.
60. Yanagihara Y, Shida T. Immunological studies on patients who received aprotinin therapy. Jpn J Allergy 1985;34.899-904.
61. Higgins TL. Pharmacologic support for postoperative low cardiac output. Semin Thorac Cardiovasc Surg 1991;3:13-23.
62. Royston D. Intraoperative coronary thrombosis; can aprotinin be incriminated? J Cardiothorac Vasc Anesth 1994;8:137-41.
63. Gravlee GP, Anticoagulation for cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, eds. Cardiopulmonary bypass. Baltimore: Williams and Wilkins, 1993:340-80.
64. Tabuchi N, Njo TL, Tigchelaar I, Huyzen RJ, Boonstra PW, van Oeveren W. Monitoring of anticoagulation in aprotinin-treated patients during heart operation. Ann Thorac Surg 1994;58:774-7.
65. Dietrich W, Jochum M. Effect of Celite and kaolin on activated clotting time in the presence of aprotinin. activated clotting time is reduced by binding of aprotinin to kaolin. J Thorac Cardiovasc Surg 1995;109:177-86.
66. Horrow JC. Management of coagulopathy associated with cardiopulmonary bypass. In: Gravlee GP, Davis RF, Utley JR, eds. Cardiopulmonary bypass. Baltimore: Williams and Wilkins, 1993:436-66.
67. Tatar H, Cicek S, Dermirkilic U, Özal E, Süer H, Öztürk Ö, et al. Topical use of aprotinin in open heart operations. Ann Thorac Surg 1993;55:659-61
68. O'Reagan DJ, Giannopoulos N, Mediratta N, Kendall SWH, Forni A, Pillai R, et al. Topical aprotinin in cardiac operations. Ann Thorac Surg 1994;58:778-81.